Betnovate for Eczema: How It Works, Uses, Strength and Side Effects
Key fact: Betnovate contains betamethasone valerate 0.1% — a potent (Class 3) topical corticosteroid available on prescription in the UK. It is the second most potent class in the UK four-class system, significantly stronger than over-the-counter hydrocortisone but less potent than Dermovate (clobetasol propionate 0.05%). It is used to treat moderate-to-severe inflammatory skin conditions including eczema, contact dermatitis, and psoriasis.
0.1%
Betamethasone valerate — the active ingredient in every Betnovate formulation
Class 3
Potent — second strongest category in the UK four-class topical steroid system
48–72h
Typical onset of visible improvement with correct application
What is Betnovate?
Betnovate is a prescription-only topical corticosteroid manufactured by Stiefel (a GSK company). Its active ingredient is betamethasone valerate 0.1% — a synthetic corticosteroid that belongs to the potent (Class 3) category in the United Kingdom’s four-class system for ranking topical steroid strength. It is available in three licensed formulations: cream, ointment, and scalp application (lotion).
As a Class 3 potent corticosteroid, Betnovate sits above both hydrocortisone (Class 1, mild) and clobetasone butyrate (Eumovate, Class 2, moderate), yet falls short of the very potent clobetasol propionate (Dermovate, Class 4). It is the natural next step when a mild or moderate steroid has failed to bring a flare under adequate control, but the risk profile of a Class 4 agent is not yet warranted.
Because of its strength, Betnovate is available on prescription only in the UK. Unlike hydrocortisone 1%, it cannot be purchased over the counter. A prescriber — whether a GP, dermatologist, or online clinical service such as Access Doctor — must assess the patient and confirm that Betnovate is appropriate before it can be dispensed.
The name “Betnovate” is the brand used widely in the UK; healthcare professionals and patients alike use it interchangeably with the generic name betamethasone valerate. The cream and ointment are most commonly prescribed for body eczema, psoriasis, and contact dermatitis, while the scalp application targets inflamed, itchy scalp conditions. For a dedicated guide to the lotion formulation, see our article on Betnovate scalp lotion.
How Betnovate Works
Betamethasone valerate is a halogenated glucocorticoid whose anti-inflammatory effects operate at the level of gene transcription within skin cells.
When Betnovate cream or ointment is applied to the skin, the active molecule penetrates the stratum corneum (the outer, protective layer of the skin) and diffuses into the cells of the underlying epidermis and dermis. Inside these cells, betamethasone valerate binds to intracellular glucocorticoid receptors (GRs) located in the cytoplasm. The resulting drug–receptor complex undergoes a conformational change that allows it to translocate into the cell nucleus.
Once inside the nucleus, the activated complex acts as a transcription factor. It binds to specific DNA sequences called glucocorticoid response elements (GREs) and simultaneously suppresses the transcription of a broad range of pro-inflammatory mediators. Key targets include:
- Interleukins IL-1, IL-2, IL-4, IL-6, and IL-31 — cytokines that drive the inflammatory cascade and itch signalling in eczema
- Tumour necrosis factor alpha (TNF-α) — a master regulator of inflammation that amplifies immune cell recruitment to the skin
- Phospholipase A2 — an enzyme whose inhibition reduces synthesis of both prostaglandins and leukotrienes, the lipid mediators responsible for vasodilation, pain, and itch
In parallel, betamethasone valerate produces vasoconstriction of superficial dermal capillaries. This directly reduces the erythema (redness) and warmth associated with acute inflammation — a clinically visible sign that the medication is working. The vasoconstriction test is in fact the standard pharmacological method used to rank relative topical steroid potency.
Together, these actions reduce the four cardinal signs of eczema: redness, swelling, itch, and scaling. Most patients notice a meaningful improvement within 48 to 72 hours of starting correct treatment; full resolution of an acute flare typically takes 7 to 14 days of regular application.
What Conditions Does Betnovate Treat?
Betnovate is licensed for inflammatory skin conditions that respond to topical corticosteroids and are of sufficient severity to require a potent agent. The main indications from the Summary of Product Characteristics (SPC) are as follows.
Atopic Eczema
Moderate-to-severe flares on the trunk, limbs, and hands that have not responded adequately to mild or moderate topical steroids. Betnovate is used for short courses to bring acute flares under control.
Contact Dermatitis
Both allergic contact dermatitis (e.g. nickel, fragrances, rubber) and irritant contact dermatitis in the acute and subacute phases, where significant inflammation, itch, and vesiculation are present.
Discoid Eczema
Also called nummular eczema, this presents as coin-shaped, crusted, and extremely itchy plaques. The chronic and lichenified nature of discoid eczema often requires a potent steroid to achieve adequate penetration and resolution.
Lichen Planus
A chronic inflammatory condition characterised by violaceous, flat-topped, intensely itchy papules and plaques. Betnovate helps suppress the T-cell-mediated immune attack on keratinocytes that drives this condition.
Psoriasis
Plaque psoriasis on the trunk and limbs responds well to potent topical steroids. Betnovate should not be used on the face, scalp (without the dedicated scalp application), or flexures without specialist guidance, as psoriasis in these areas behaves differently.
Seborrhoeic Dermatitis
For scalp involvement, the Betnovate Scalp Application (lotion) is the preferred formulation; see the dedicated Betnovate lotion for scalp eczema and seborrhoeic dermatitis guide. On the trunk or face (if prescribed), the cream formulation may be used under close supervision.
Insect Bite Reactions
Severe or slow-resolving inflammatory reactions to insect bites — particularly those with marked swelling, intense itch, and blistering — may respond to a short course of a potent topical steroid when milder preparations have been ineffective.
Other Inflammatory Dermatoses
A number of other steroid-responsive dermatoses — including pompholyx, prurigo nodularis, and hypertrophic lichen simplex — may be treated with Betnovate at a prescriber’s discretion when the clinical picture warrants a potent agent.
Betnovate Formulations
Betnovate is available in three formulations, all containing betamethasone valerate 0.1%. Choosing the right base is as clinically important as selecting the right strength, because the vehicle affects both drug delivery and how the preparation interacts with the skin’s moisture state.
| Formulation | Base type | Best suited for | Notes |
|---|---|---|---|
| Cream 0.1% | Water-in-oil emulsion (contains chlorocresol as preservative) | Moist, weeping, or acutely inflamed eczema; daytime use; visible, non-hairy areas | Lighter texture; cosmetically acceptable; may contain preservatives that occasionally cause sensitisation |
| Ointment 0.1% | Anhydrous paraffin base (no preservatives) | Dry, thickened (lichenified), chronic, or scaling eczema and psoriasis | More occlusive; enhances drug penetration; preferred for dry/fissured skin; less suitable for moist/flexural areas |
| Scalp Application (Lotion) 0.1% | Aqueous/alcoholic solution | Scalp eczema, psoriasis, and seborrhoeic dermatitis; any hair-bearing area | Full guidance in our dedicated applying Betnovate lotion to hairy skin article |
In clinical practice, the cream is usually the first choice for acute flares because it feels lighter and is easier to apply to visible body areas. The ointment is preferred for chronic, lichenified plaques: its greasy, occlusive base holds moisture in the skin and improves drug penetration through thickened, keratinised skin. Neither cream nor ointment is suitable for the scalp — the lotion formulation is specifically designed for hair-bearing skin and spreads without matting hair or leaving a residue.
A lower-strength version, Betnovate RD (betamethasone valerate 0.025%, cream and ointment), is also available. This contains one-quarter of the steroid concentration and sits in Class 2 (moderate), making it a useful step-down option once a flare has been brought under control with Betnovate 0.1%, or as a maintenance preparation where ongoing treatment is needed on areas that are more susceptible to side effects.
Betnovate on the UK Topical Steroid Potency Ladder
The UK classifies topical corticosteroids into four potency classes based on the vasoconstriction assay and clinical efficacy data. This classification, used by the British National Formulary (BNF), NICE, and NHS prescribing guidelines, is the foundation for safe steroid prescribing. Understanding where Betnovate sits on this ladder helps patients and clinicians make appropriate treatment decisions.
| Class | Potency | Example products | Typical use |
|---|---|---|---|
| Class 1 | Mild | Hydrocortisone 0.5%, 1%, 2.5% | First-line for mild eczema, face & children; available OTC at 1% |
| Class 2 | Moderate | Clobetasone butyrate 0.05% (Eumovate); Betamethasone valerate 0.025% (Betnovate RD) | Mild-to-moderate eczema not controlled by hydrocortisone; some facial use |
| Class 3 | Potent | Betamethasone valerate 0.1% (Betnovate); Mometasone furoate 0.1% (Elocon); Fluocinolone acetonide 0.025% | Moderate-to-severe eczema, contact dermatitis, psoriasis on trunk & limbs; prescription only |
| Class 4 | Very potent | Clobetasol propionate 0.05% (Dermovate); Halcinonide 0.1% | Severe, refractory eczema or psoriasis; short courses only; specialist supervision often needed |
Treatment should be stepped up only when the current strength has genuinely failed after an adequate trial, and stepped down as soon as the skin is under control. Using a more potent steroid than necessary adds nothing and increases the risk of side effects. For most adults with a moderate eczema flare on the body, Betnovate (Class 3) is the appropriate choice once Class 1 or Class 2 has proved insufficient.
Class 3 includes several other potent agents alongside Betnovate — most notably mometasone furoate (Elocon). Clinical guidelines treat these as broadly equivalent in potency, though formulation, vehicle, and individual patient factors will influence the prescriber’s choice.
How to Use Betnovate Safely
Correct application technique is essential to maximising efficacy while minimising the risk of local and systemic side effects. The following guidance reflects the NHS, BNF, and EMC SPC recommendations.
1
Apply a thin smear to affected skin only
Betnovate should never be applied liberally. A thin layer — just enough to cover and slightly glisten the skin — is both effective and safe. Applying more does not work better; it simply increases absorption and systemic risk. Do not apply to healthy skin surrounding the affected area.
2
Use once or twice daily
The licensed dosing is once or twice daily. For most patients, once daily (ideally in the evening after washing) is as effective as twice daily and reduces total steroid exposure. Your prescriber will confirm the appropriate frequency for your condition.
3
Use the fingertip unit (FTU) to gauge the amount
A fingertip unit is the amount of cream squeezed from a standard tube nozzle along the tip of an adult index finger — approximately 0.5g. One FTU treats roughly two adult palms of skin. For a hand (both sides): 1 FTU. For an arm: 3 FTUs. For a leg: 6 FTUs. For the trunk (front or back): 7 FTUs each. Use these as a maximum guide, not a target.
4
Observe the facial maximum of four weeks
If Betnovate is prescribed for facial skin, it should not be used for more than four weeks without a prescriber review. The face is more susceptible to steroid-induced skin thinning, perioral dermatitis, and rosacea than other body areas. In practice, Class 3 steroids are rarely first-line for facial eczema; a Class 1 or Class 2 agent is usually tried first.
5
Avoid flexures, eyelids, and genitals unless specifically directed
Skin in the axillae (armpits), groin, between the buttocks, and on the eyelids is naturally thinner and more occlusive. Topical steroids are more readily absorbed in these areas, and the risk of side effects is proportionally higher. Use in flexures requires specialist advice.
6
Do not use under occlusion unless instructed
Covering Betnovate with a bandage, cling film, or tight clothing significantly increases percutaneous absorption — potentially by a factor of 10 or more. Occlusive dressings with potent topical steroids are occasionally used clinically for resistant plaques but only under direct medical supervision.
7
Respect the weekly quantity limits
As a guide, the British National Formulary and dermatology guidelines suggest a maximum of approximately 30–60g per week for body use, depending on the area treated and the clinical indication. Regular prescriptions exceeding these quantities should be reviewed by the prescribing clinician.
8
Step down as the skin improves
Once the flare is under control, step down to a weaker steroid (or use Betnovate on alternate days or weekends only) before stopping. Abrupt cessation after prolonged use of a potent steroid can cause a rebound flare. Continue moisturising daily as part of ongoing skin maintenance.
Face and flexures: Betnovate is generally not recommended for the face or skin folds (armpits, groin, under the breasts) without specialist advice. These areas have thinner skin and higher absorption, increasing the risk of skin thinning, stretch marks, and perioral dermatitis. If your prescriber has specifically prescribed it for these areas, use it for the shortest duration possible and review promptly.
Get Betnovate Online via Access Doctor
Access Doctor is a GPhC-registered online pharmacy (#9011198) with GMC-registered prescribers. Complete a short clinical consultation online and, if appropriate, receive your prescription for Betnovate cream or ointment with next-day delivery.
Start ConsultationPrescription Treatment
Betnovate Cream
Betamethasone valerate 0.1% — potent steroid for moderate-to-severe eczema and dermatitis
View treatment →Related Guide
Betnovate Lotion for the Scalp
Application guide for scalp eczema and seborrhoeic dermatitis
Read guide →Side Effects of Betnovate
Used correctly and for appropriate durations, Betnovate is well tolerated. As a potent topical corticosteroid it carries a recognised side-effect profile, most of which is related to prolonged use or application to the wrong areas.
Local (skin) side effects
These are the most clinically relevant side effects and are almost always related to prolonged use, overuse, or inappropriate application to sensitive areas.
- Skin thinning (atrophy): The skin becomes fragile, translucent, and bruises easily. This is caused by the inhibition of collagen synthesis by fibroblasts. It is reversible if Betnovate is stopped early but may be permanent with prolonged misuse.
- Striae (stretch marks): Irreversible purplish or silvery linear marks caused by dermal atrophy and loss of skin elasticity, particularly in flexural areas. They do not resolve fully once formed.
- Telangiectasia: Permanently dilated superficial blood vessels, visible as fine red or purple thread-like lines on the skin surface, particularly on the face.
- Perioral dermatitis: A papulopustular eruption around the mouth, sometimes spreading to the nasal folds and chin, associated with inappropriate steroid application to the face.
- Acneiform eruption: Steroid-induced acne characterised by uniform small papules and pustules, particularly on the trunk and face.
- Hypertrichosis: Localised increase in hair growth at the site of application, due to the stimulatory effect of steroids on hair follicles.
- Hypopigmentation: Lightening of the skin in the treated area, more clinically noticeable in patients with darker skin tones.
- Contact sensitisation: Although rare, some patients may develop an allergic reaction to betamethasone valerate or the preservatives in the cream base (particularly chlorocresol). If the skin worsens or develops a new pattern of inflammation, allergy should be considered.
Systemic side effects
Systemic absorption is generally minimal when betamethasone valerate is applied to small, intact areas for short periods. It becomes clinically relevant when large body surface areas are treated, when the preparation is used under occlusion, or when use is prolonged without review.
- HPA axis suppression: Exogenous glucocorticoids suppress the hypothalamic-pituitary-adrenal (HPA) axis via negative feedback. Prolonged topical steroid use may reduce the body’s ability to mount a normal cortisol stress response. Clinically significant suppression is uncommon with Betnovate used as directed.
- Adrenal suppression and Cushingoid features: In cases of prolonged and excessive use — particularly in children or with occlusion — systemic features including weight gain, fluid retention, hypertension, and glucose dysregulation may rarely occur.
- Raised intraocular pressure / glaucoma / cataracts: Repeated application near the eyes or to the eyelids can increase intraocular pressure, potentially precipitating glaucoma or accelerating cataract formation. Betnovate should never be applied directly to the eyelids or the periorbital area without specialist instruction.
- Adrenal crisis on abrupt withdrawal: After prolonged, extensive use, abrupt discontinuation can unmask HPA suppression and precipitate an adrenal crisis — though this is rare with topical use and is more of a consideration in patients who are also taking other forms of corticosteroids.
Who Should Not Use Betnovate?
Do not use Betnovate if you have an untreated skin infection. Applying a topical steroid to infected skin — whether bacterial, fungal, or viral — will suppress the immune response and allow the infection to spread and worsen, sometimes dramatically. Treat the infection first, then reassess the need for a steroid.
Betnovate is contraindicated in the following situations, as listed in the licensed SPC and BNF:
- Untreated bacterial skin infections (e.g. impetigo, cellulitis) — use will spread the infection
- Untreated fungal skin infections (e.g. tinea, candidiasis) — potent steroids dramatically worsen tinea infections (“tinea incognito”)
- Viral skin infections (e.g. herpes simplex, chickenpox, shingles) — steroids suppress local immunity and may cause dissemination
- Acne vulgaris — topical steroids worsen acne and can cause steroid acne (acneiform eruption)
- Rosacea — may cause initial apparent improvement but leads to rebound worsening and steroid-induced rosacea
- Perioral dermatitis — topical steroids are a recognised cause of perioral dermatitis; continued use perpetuates the condition
- Known hypersensitivity to betamethasone valerate, other corticosteroids, or any excipient in the formulation
- Application to broken, ulcerated, or infected skin
- Infants under 1 year — should not be used without specialist supervision due to the proportionally larger body surface area to weight ratio and thinner, more permeable skin
- Napkin (nappy) dermatitis — the warm, moist, occluded environment of the nappy area dramatically increases steroid absorption
Betnovate in Pregnancy and Breastfeeding
The prescribing of topical corticosteroids during pregnancy and breastfeeding requires careful clinical judgement. The following reflects current BNF, NHS, and EMC SPC guidance.
Pregnancy
High-dose systemic corticosteroids are teratogenic in animals, but this is not considered directly relevant to limited topical use in humans. The risk to the foetus from a short course of betamethasone valerate applied to a small area of intact skin is low. The following precautions still apply:
- Avoid prolonged use or application to large areas of the body during pregnancy, particularly in the first trimester
- Use the smallest effective amount for the shortest necessary duration
- Avoid use under occlusion in pregnancy
- Very potent steroids (Class 4) are more restricted in pregnancy; Betnovate’s Class 3 status makes it somewhat more acceptable, but prescriber oversight remains essential
- Some observational data have associated very large quantities of potent topical steroids used throughout pregnancy with low birth weight — a further reason to use sparingly
Breastfeeding
There are no known contraindications to using Betnovate while breastfeeding, provided the cream or ointment is not applied to the breast or nipple area. Ingestion of topical steroids by the infant during feeding would carry a risk that is best avoided. Wash hands thoroughly after applying Betnovate to any area before handling an infant.
Women who are pregnant or breastfeeding should discuss their skin condition with their GP or prescriber before starting or continuing Betnovate.
Betnovate vs Dermovate: When to Step Up
Betnovate and Dermovate are the two most commonly prescribed potent and very potent topical steroids in the UK. Knowing when — and whether — to step up is central to managing expectations and avoiding unnecessary escalation of steroid potency.
| Feature | Betnovate | Dermovate |
|---|---|---|
| Active ingredient | Betamethasone valerate 0.1% | Clobetasol propionate 0.05% |
| UK potency class | Class 3 — Potent | Class 4 — Very Potent |
| Relative potency | Substantially more potent than hydrocortisone (Class 1); precise multipliers vary by assay and are not stated in the SPC | More potent again than betamethasone valerate 0.1%; the most potent class of topical steroid routinely available in the UK |
| Typical indications | Moderate-to-severe atopic eczema, contact dermatitis, discoid eczema, lichen planus, psoriasis on trunk/limbs | Severe refractory eczema; lichen sclerosus; severe psoriasis; conditions unresponsive to Betnovate |
| Maximum course (face) | 4 weeks | Generally not recommended on the face |
| Systemic risk | Low with correct short-course use | Higher; HPA suppression more likely with extended use |
| Available OTC? | No — prescription only | No — prescription only |
For moderate-to-severe eczema on the body, Betnovate is generally the appropriate starting point once Class 1–2 agents have failed. Moving to Dermovate is reasonable when a patient has completed an adequate trial — typically two to four weeks of correct use — without achieving satisfactory control. Escalating to a very potent agent without confirming the diagnosis and excluding infection risks significant side effects without necessarily improving outcomes.
When Dermovate is required, it carries a higher risk of systemic absorption and HPA axis effects, particularly if large areas are treated or use extends beyond the recommended duration. For a full clinical guide to how clobetasol propionate works and when it is appropriate, see our article on how Dermovate works — and when to step up from Betnovate.
In practice, escalating to Dermovate should involve a prescriber review — an opportunity to confirm the diagnosis, exclude infection, and check that application technique and quantity have been adequate before reaching for a Class 4 agent.
Getting Betnovate Online via Access Doctor
Access Doctor is a GPhC-registered online pharmacy (pharmacy registration number 9011198) that provides regulated online consultations with GMC-registered prescribers. Betnovate cream and ointment are available via this service for patients who require a prescription.
The consultation process follows the same clinical standards as a face-to-face appointment:
1
Complete the online consultation
Answer a structured set of clinical questions about your skin condition, previous treatments, medical history, allergies, and current medications. This takes approximately 5 minutes and is reviewed by a qualified prescriber.
2
Prescriber assessment
A GMC-registered doctor reviews your consultation. They will assess whether Betnovate is appropriate, consider whether any contraindications are present, and determine the correct formulation and quantity for your needs. They may follow up with additional questions if required.
3
Prescription issued and dispensed
If the prescriber determines that Betnovate is clinically appropriate, a prescription is issued and dispensed by the GPhC-registered Access Doctor pharmacy. All prescriptions comply with UK regulatory requirements.
4
Next-day delivery
Your medication is dispatched in discreet packaging and delivered to your home. Next-day delivery is available for orders placed before the cut-off time. Full prescribing information and usage instructions are included with every order.
Frequently Asked Questions
1. What is Betnovate used for?
Betnovate is used to treat a range of inflammatory skin conditions including atopic eczema (moderate-to-severe flares), contact dermatitis (allergic and irritant), discoid (nummular) eczema, lichen planus, plaque psoriasis on the trunk and limbs, seborrhoeic dermatitis (particularly on the scalp, using the lotion formulation), and severe or slow-resolving insect bite reactions. It is prescribed when milder topical steroids such as hydrocortisone or Eumovate have not provided adequate control.
2. How strong is Betnovate compared to other steroid creams?
Betnovate is a Class 3 potent topical corticosteroid in the UK’s four-class potency system. It is considerably stronger than over-the-counter hydrocortisone 1% (Class 1, mild) and stronger than Eumovate clobetasone butyrate (Class 2, moderate). It is less potent than Dermovate (clobetasol propionate 0.05%, Class 4, very potent), which is the strongest class of topical steroid routinely available. Ranking by precise potency ratios varies by assay method and is not stated in the Betnovate SPC; the BNF classification is the clinically relevant guide.
3. How quickly does Betnovate work?
Most patients begin to notice a reduction in redness, itch, and swelling within 48 to 72 hours of starting correct twice-daily application. This early improvement reflects the vasoconstriction and early anti-inflammatory effects of betamethasone valerate. Full resolution of a moderate eczema flare typically takes 7 to 14 days. If there is no improvement after two weeks of correct use, this should be reviewed by a prescriber — the diagnosis may need to be reconsidered or a stronger preparation may be required.
4. How long can I use Betnovate?
Betnovate should be used for the shortest effective period. For facial skin, a maximum of four weeks is recommended without medical review. For body skin, longer supervised courses are sometimes appropriate, but regular prescriber review is essential. Prolonged unsupervised use — particularly in children, on the face, or in flexural areas — carries a risk of skin thinning, striae, and (with large quantities) systemic effects. Once the skin is under control, dose frequency should be reduced and a weaker preparation used as maintenance if ongoing treatment is needed.
5. What are the side effects of Betnovate cream?
Local side effects of Betnovate include skin thinning (atrophy), stretch marks (striae), telangiectasia (thread veins), perioral dermatitis (around the mouth when used on the face), acneiform eruption, hypertrichosis (increased hair growth at the application site), and hypopigmentation (lightening of the skin). Systemic side effects are rare with correct short-course use but can include HPA axis suppression and, very rarely with excessive long-term use, Cushingoid features. The risk of all side effects is minimised by using the smallest effective amount, for the shortest necessary duration, on the appropriate body areas.
6. Can I use Betnovate on my face?
Betnovate can be prescribed for use on the face, but it is not a first-line choice for facial eczema. The face has thinner skin and higher steroid absorption, making it more susceptible to side effects including skin thinning, telangiectasia, perioral dermatitis, and rosacea exacerbation. If Betnovate is prescribed for the face, it should be used for a maximum of four weeks, sparingly, and not on the eyelids. In most cases, a Class 1 or Class 2 steroid is tried on the face first. Always follow your prescriber’s specific instructions for facial use.
7. Can I use Betnovate during pregnancy?
Betnovate is not absolutely contraindicated in pregnancy, but caution is advised. The risk from short-course, small-area topical use is considered low. However, prolonged application to large body surface areas in pregnancy should be avoided due to the potential risk of foetal growth restriction associated with high cumulative steroid exposure. If you are pregnant or planning to become pregnant, discuss your skin condition with your prescriber so that treatment can be appropriately tailored to balance maternal benefit with minimal foetal risk.
8. What is the difference between Betnovate cream and ointment?
Both contain the same active ingredient (betamethasone valerate 0.1%) at the same concentration, so they are therapeutically equivalent in terms of potency. The key difference lies in the base. The cream is a water-in-oil emulsion — lighter in texture, cosmetically more acceptable, and better suited to moist, weeping, or acutely inflamed skin. The ointment has an anhydrous paraffin base — more occlusive, better at maintaining skin hydration, and preferred for dry, thickened, lichenified, or chronic plaques. The ointment also contains no preservatives, making it marginally less likely to cause preservative-related contact sensitisation.
9. Can I use Betnovate and Dermovate together?
No — Betnovate and Dermovate should not be used simultaneously on the same area of skin. They both contain potent or very potent topical corticosteroids; using both together would increase systemic absorption and the risk of side effects without providing additional benefit. In some cases, a prescriber may direct a patient to use a different strength product on different body areas — for example, a mild steroid on the face and Betnovate on the body — but this requires explicit clinical guidance and clear patient understanding of which product to apply where.
10. Can I get Betnovate without a prescription in the UK?
No. Betnovate (betamethasone valerate 0.1%) is a prescription-only medicine (POM) in the United Kingdom. It cannot be purchased from a pharmacy without a valid prescription from a GMC-registered prescriber. This applies to all three formulations — cream, ointment, and scalp application. Lower-potency betamethasone preparations (such as betamethasone valerate 0.025%) are available in some pharmacies as pharmacy-only medicines, but these are in a different potency class. Access Doctor offers a regulated online prescription service through which eligible patients can obtain Betnovate after a clinical assessment.
References
- Electronic Medicines Compendium (EMC). Betnovate Cream 0.1% Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/604
- Electronic Medicines Compendium (EMC). Betnovate Ointment 0.1% Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/605
- British National Formulary (BNF). Betamethasone (topical). https://bnf.nice.org.uk/drugs/betamethasone/
- NICE CKS. Eczema — atopic. https://cks.nice.org.uk/topics/eczema-atopic/
- NICE CKS. Psoriasis. https://cks.nice.org.uk/topics/psoriasis/
- NHS. Betamethasone skin cream, ointment and lotion. https://www.nhs.uk/medicines/betamethasone-skin/
- NHS. Topical corticosteroids. https://www.nhs.uk/conditions/topical-corticosteroids/
Important: Betnovate (betamethasone valerate 0.1%) is a prescription-only medicine in the United Kingdom. This article is for informational purposes only and does not constitute medical advice or replace a clinical consultation with a qualified healthcare professional. Always read the patient information leaflet supplied with your medication. If you have any questions about your treatment, contact your prescriber or pharmacist. In an emergency, call 999 or attend your nearest A&E department.